Navigation Links
TechAtlas Group Releases Hepatitis C Competitive Landscape Analysis
Date:8/21/2013

BOSTON, Aug. 21, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest Hepatitis C (HCV) competitive landscape map. This particular landscape highlights 25 international companies with over 60 drugs and combinations currently on the market and in development.

(Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO )

Topics include:

  • Winning the HCV race
  • Gilead: the one to beat
  • Debate over what is "Good Enough"
  • Other nukes
  • Leading nuke-less regimens
  • Strategic Implications of Worldwide genotype distribution
  • HCV all-oral combination timeline
  • Competitive positioning and rationale for partnerships and M&A

TechAtlas' analysts have evaluated each clinical asset and combination regimen according to the parameters that dictate their commercial competitiveness, including clinical benefit/risk, cost, patient preference, and reimbursement dynamics. For example, all companies are striving to win the HCV race with an all-oral, genotype-1 or pan-genotypic regimen that is convenient (QD), well-tolerated, highly effective (>90% SVR), as short as possible (12 weeks or less), has few drug-drug interactions (DDI), and works well even in patients with subclinical cirrhosis. Such a regimen could be prescribed by primary physicians with little more information than just a confirmation that the patient has HCV and possibly the viral genotype, allowing far more patients to be treated and cured than the current limited bandwidth of specialists allows, not just in the US and Europe but also in China, Egypt, and other countries were HCV is prevalent but where medical care is not as "high-touch". If multiple regimens achieve "optimal" status, or even come close, then the leaders will be at the mercy of followers willing to cut price to gain market share. But there is going to be considerable debate over what is "good enough" such that payors could push for cost-savings without being seen as compromising patient care.

The TechAtlas map graphically presents every HCV-related technology, old and new, in its proper context to clearly show the relationship of competing and complementary products for specific unmet needs and a timeline of upcoming clinical milestones as well as expected earliest sales dates through 2017. This map was built on extensive primary research, including interviews with companies, investors, key opinion leaders in the hepatology and infectious disease community, academic researchers, technical experts, consumers of technologies, and other stakeholders in the field, as well as an exhaustive review of public and proprietary resources.

TechAtlas Group's current subscribers have reported that their researchers, business development executives, and senior management have used the maps to guide their business development efforts, R&D resource allocation, and competitive positioning.

Some of the 25 companies featured on the TechAtlas HCV landscape include: AbbVie, Achillion, BMS, Boehringer Ingelheim, Enanta, Gilead, GSK, Idenix, Johnson & Johnson, Merck, Novartis, Presidio, Roche, Scynexis and Vertex.  

For further information on obtaining a copy of this report through an annual subscription, please consult our website: http://www.techatlasgroup.com/order.html

About TechAtlas Group
TechAtlas Group, LLC brings a novel, multi-dimensional, visually stimulating approach to decision makers who are already flooded with data and information but are seeking context and actionable insight to guide their resource allocation for R&D and commercial activities. Founded in 2011, TechAtlas Group, LLC is headquartered in Boston, MA.  Their large team of PhDs is trained to analyze the viability and commercial competitiveness of a variety of technologies and distill their insights into a visual landscape.  As each field evolves, the maps are updated and issued to subscribers.  The TechAtlas mission is to convey in one dynamic diagram what has conventionally been crammed into a static 100-page report.


'/>"/>
SOURCE TechAtlas Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
2. New Survey: Hispanic Teen Drug Use Significantly Higher Than Other Ethnic Groups, Substance Abuse Becoming Normalized Behavior Among Latino Youth
3. CompuGroup Medical US Announces New Laboratory Information System for the Reference Laboratory, CGM ENDEAVOR
4. Yew Bio-Pharm Group Announces Second-Quarter 2013 Results
5. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
6. AtlantiCare Heart Heroes group donates Cardiac Science AED to Atlantic City public access defibrillation program
7. Hoosier Oncology Group Selects OnCore to Support Clinical Trials Network
8. Linde Distributor Association, at twenty, is a leading buying group in the U.S.
9. CAO Group Continues to Lead Innovation With launch of New, High Technology Turbo Forensic Light System
10. Orange County Physician Owned Medical Group Opens Pioneering Medical Facility
11. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Global Immunology Market to 2022 - ... market growth Summary Immune-mediated inflammatory diseases ... that affect 5–7% of western populations. Although they ... and key patient demographics, they are pathophysiologically linked, ... an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... , ... The American public tends to feel uncomfortable about drinking recycled waste ... or well water. The recent experience with lead contaminated water in Flint, Michigan, according ... toward increasing public acceptance of recycled waste water as drinking water. , The ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and ... 2nd Annual No Cost Dental Day to individuals in need. The event is scheduled ... this No Cost Dental Day is to provide dental care to community members in ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a web ... zone to the next using Colorize's dynamic moving camera. Colorize is perfect for personal ... a 3D slideshow environment with 1 to 5 focus points per scene, stage floor ...
(Date:2/5/2016)... ... , ... California Mobile Kitchens , a company that ... mobile kitchen model, featuring customizable stainless steel interiors and a new, 26-foot unit. ... anywhere in the U.S. Many of their units can be seen at sporting ...
Breaking Medicine News(10 mins):